Antibacterial Drug - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antibacterial Drug

The Experts below are selected from a list of 28446 Experts worldwide ranked by ideXlab platform

Antibacterial Drug – Free Register to Access Experts & Abstracts

George Psomas – One of the best experts on this subject based on the ideXlab platform.

  • zinc ii complexes with the quinolone Antibacterial Drug flumequine structure dna and albumin binding
    New Journal of Chemistry, 2013
    Co-Authors: Alketa Tarushi, Jakob Kljun, Iztok Turel, Anastasia A. Pantazaki, George Psomas, Dimitris P Kessissoglou

    Abstract:

    The interaction of Zn(II) with the quinolone Antibacterial Drug flumequine (Hflmq) in the presence or absence of an N,N′-donor heterocyclic ligand, 2,2′-bipyridine (bipy), is being investigated. Interaction of equimolar quantities of ZnCl2 with flumequine and 2,2′-bipyridine results in the formation of a structurally characterized [Zn(flmq)(bipy)Cl] (2) complex, while excess of flumequine leads to a structurally characterized [Zn(flmq)2(bipy)] (3) compound. The reaction of ZnCl2 with flumequine in the absence of 2,2′-bipyridine leads to formation of complex [Zn(flmq)2(H2O)2] (1). In all these complexes, the deprotonated bidentate flumequinato ligands are coordinated to zinc ions through pyridone and carboxylato oxygens. The complexes exhibit good binding propensity to human or bovine serum albumin protein having relatively high binding constant values. UV study of interaction of the complexes with calf-thymus DNA (CT DNA) has shown that they bind to CT DNA and [Zn(flmq)(bipy)Cl] exhibits the highest binding constant. A competitive study with ethidium bromide (EB) has shown that the complexes can displace DNA-bound EB, indicating that they bind to DNA in strong competition with EB. The complexes bind to CT DNA in an intercalative binding mode which has also been verified by DNA solution viscosity measurements. DNA electrophoretic mobility experiments showed that all complexes bind to pDNA possibly in an intercalative manner resulting in catenanes formation as well as in double-stranded cleavage reflecting (or ending) in the formation of linear DNA.

  • zinc ii complexes of the second generation quinolone Antibacterial Drug enrofloxacin structure and dna or albumin interaction
    Bioorganic & Medicinal Chemistry, 2010
    Co-Authors: Alketa Tarushi, George Psomas, Catherine P. Raptopoulou, Vassilis Psycharis, Aris Terzis, Dimitris P Kessissoglou

    Abstract:

    Zinc mononuclear complexes with the second-generation quinolone Antibacterial Drug enrofloxacin in the absence or presence of a nitrogen donor heterocyclic ligand 1,10-phenanthroline or 2,2′-bipyridine have been synthesized and characterized. Enrofloxacin is on deprotonated mode acting as a bidentate ligand coordinated to zinc ion through the ketone and a carboxylato oxygen atoms. The crystal structure of bis(enrofloxacinato)(1,10-phenanthroline)zinc(II), 2, has been determined by X-ray crystallography. The biological activity of the complexes has been evaluated by examining their ability to bind to calf-thymus DNA (CT DNA) with UV and fluorescence spectroscopies. UV studies of the interaction of the complexes with DNA have shown that they can bind to CT DNA and the DNA binding constants have been calculated. Competitive studies with ethidium bromide (EB) have shown that the complexes exhibit the ability to displace the DNA-bound EB indicating that they bind to DNA in strong competition with EB for the intercalative binding site. The complexes exhibit good binding propensity to human and bovine serum albumin proteins having relatively high binding constant values.

  • zinc complexes of the Antibacterial Drug oxolinic acid structure and dna binding properties
    Journal of Inorganic Biochemistry, 2009
    Co-Authors: Alketa Tarushi, George Psomas, Catherine P. Raptopoulou, Dimitris P Kessissoglou

    Abstract:

    The neutral mononuclear zinc complexes with the quinolone Antibacterial Drug oxolinic acid in the absence or presence of a nitrogen donor heterocyclic ligand 2,2′-bipyridine or 1,10-phenanthroline have been synthesized and characterized. The experimental data suggest that oxolinic acid is on deprotonated mode acting as a bidentate ligand coordinated to the metal ion through the ketone and one carboxylato oxygen atoms. The crystal structures of (chloro)(oxolinato)(2,2′-bipyridine)zinc(II), 2, and bis(oxolinato)(1,10-phenanthroline)zinc(II), 3, have been determined with X-ray crystallography. The biological activity of the complexes has been evaluated by examining their ability to bind to calf-thymus DNA (CT DNA) with UV and fluorescence spectroscopies. UV studies of the interaction of the complexes with DNA have shown that they can bind to CT DNA and the DNA-binding constants have been calculated. Competitive studies with ethidium bromide (EB) have shown that complex 3 exhibits the ability to displace the DNA-bound EB indicating that it binds to DNA in strong competition with EB.

Matylda Zietek – One of the best experts on this subject based on the ideXlab platform.

  • Species-specific activity of Antibacterial Drug combinations
    Nature, 2018
    Co-Authors: Ana Rita Brochado, Anja Telzerow, Jacob Bobonis, Manuel Banzhaf, Joel Selkrig, Emily Huth, Stefan Bassler, Jordi Zamarreño Beas, André Mateus, Matylda Zietek

    Abstract:

    Screening pairwise combinations of antibiotics and other Drugs against three bacterial pathogens reveals that antagonistic and synergistic DrugDrug interactions are specific to microbial species and strains. The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine^ 1 , 2 . Drug combinations can help to fight multi-Drug-resistant bacterial infections, yet they are largely unexplored and rarely used in clinics. Here we profile almost 3,000 dose-resolved combinations of antibiotics, human-targeted Drugs and food additives in six strains from three Gram-negative pathogens— Escherichia coli , Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa —to identify general principles for Antibacterial Drug combinations and understand their potential. Despite the phylogenetic relatedness of the three species, more than 70% of the DrugDrug interactions that we detected are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between Drugs that target different cellular processes, whereas synergies are more conserved and are enriched in Drugs that target the same process. We provide mechanistic insights into this dichotomy and further dissect the interactions of the food additive vanillin. Finally, we demonstrate that several synergies are effective against multi-Drug-resistant clinical isolates in vitro and during infections of the larvae of the greater wax moth Galleria mellonella , with one reverting resistance to the last-resort antibiotic colistin.

  • Species-specific activity of Antibacterial Drug combinations
    Nature, 2018
    Co-Authors: Ana Rita Brochado, Anja Telzerow, Jacob Bobonis, Manuel Banzhaf, Joel Selkrig, Emily Huth, Stefan Bassler, Jordi Zamarreño Beas, André Mateus, Matylda Zietek

    Abstract:

    The spread of antimicrobial resistance has become a serious public health concern, making once treatable diseases deadly again and undermining breakthrough achievements of modern medicine 1,2. Drug combinations can aid in fighting multi-Drug resistant (MDR) bacterial infections, yet, are largely unexplored and rarely used in clinics. To identify general principles for Antibacterial Drug combinations and understand their potential, we profiled ~3,000 dose-resolved combinations of antibiotics, human-targeted Drugs and food additives in 6 strains from three Gram-negative pathogens, Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Despite their phylogenetic relatedness, more than 70% of the detected DrugDrug interactions are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between Drugs targeting different cellular processes, whereas synergies are more conserved and enriched in Drugs targeting the same process. We elucidate mechanisms underlying this dichotomy and further use our resource to dissect the interactions of the food additive, vanillin. Finally, we demonstrate that several synergies are effective against MDR clinical isolates in vitro and during Galleria mellonella infections with one reverting resistance to the last-resort antibiotic, colistin.

  • Species-specific activity of Antibacterial Drug combinations
    Nature, 2018
    Co-Authors: Ana Rita Brochado, Anja Telzerow, Jacob Bobonis, Manuel Banzhaf, Artur Mateus, Joel Selkrig, Emily Huth, Stefan Bassler, Jordi Zamarreño Beas, Matylda Zietek

    Abstract:

    The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine1,2. Drug combinations can help to fight multi-Drug-resistant bacterial infections, yet they are largely unexplored and rarely used in clinics. Here we profile almost 3,000 dose-resolved combinations of antibiotics, human-targeted Drugs and food additives in six strains from three Gram-negative pathogens—Escherichia coli, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa—to identify general principles for Antibacterial Drug combinations and understand their potential. Despite the phylogenetic relatedness of the three species, more than 70% of the DrugDrug interactions that we detected are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between Drugs that target different cellular processes, whereas synergies are more conserved and are enriched in Drugs that target the same process. We provide mechanistic insights into this dichotomy and further dissect the interactions of the food additive vanillin. Finally, we demonstrate that several synergies are effective against multi-Drug-resistant clinical isolates in vitro and during infections of the larvae of the greater wax moth Galleria mellonella, with one reverting resistance to the last-resort antibiotic colistin.

K Balasubramanian – One of the best experts on this subject based on the ideXlab platform.

  • polyacrylonitrile syzygium aromaticum hierarchical hydrophilic nanocomposite as a carrier for Antibacterial Drug delivery systems
    RSC Advances, 2015
    Co-Authors: Ramdayal Yadav, K Balasubramanian

    Abstract:

    Correction for ‘Polyacrylonitrile/Syzygium aromaticum hierarchical hydrophilic nanocomposite as a carrier for Antibacterial Drug delivery systems’ by Ramdayal Yadav et al., RSC Adv., 2015, 5, 3291–3298.

  • Polyacrylonitrile/Syzygium aromaticum hierarchical hydrophilic nanocomposite as a carrier for Antibacterial Drug delivery systems
    RSC Advances, 2014
    Co-Authors: Ramdayal Yadav, K Balasubramanian

    Abstract:

    Correction for ‘Polyacrylonitrile/Syzygium aromaticum hierarchical hydrophilic nanocomposite as a carrier for Antibacterial Drug delivery systems’ by Ramdayal Yadav et al., RSC Adv., 2015, 5, 3291–3298.